ALKS / Here's Why Alkermes (ALKS) Is a Great 'Buy the Bottom' Stock Now

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. more_horizontal

Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a clinical update announced more_horizontal

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment. more_horizontal

Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through more_horizontal

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. Th more_horizontal

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Tev more_horizontal

Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a more_horizontal

Alkermes plc (NASDAQ:ALKS ) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Cor more_horizontal